Seems to me GNOM is a better long-term bet on genomic advances than ARKG. GNOM has a lower ER and is likely less volatile and less inflated due to no association with Cathie Wood fanaticism. GNOM is also based on an index (Solactive Genomics Index), which suggests lower expenses over the long term. What are your thoughts? Advantages and disadvantages of each?
GNOM info from Global X's website:
FUND SUMMARY
The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
FUND OBJECTIVE
The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.
Submitted June 30, 2021 at 08:35AM by Market_Psychosis https://ift.tt/3jq825G
